NY-ESO-1 (161-180)

NY-ESO-1 (161-180) is a synthetic peptide corresponding to amino acids 161 through 180 of the cancer-testis antigen NY-ESO-1. As a member of the peptide compound category, it represents a defined epitope region within the NY-ESO-1 protein, which is widely recognized for its restricted expression in normal tissues and high prevalence in various tumor types. The sequence's immunogenic properties and its role in tumor-associated antigenicity make it a valuable reagent in tumor immunology, epitope mapping, and antigen-specific T cell research. Its defined structure and reproducibility support a range of experimental approaches in basic and applied biomedical research.

Epitope Mapping: NY-ESO-1 (161-180) is frequently utilized in the precise identification and characterization of immunogenic epitopes within the NY-ESO-1 protein. By serving as a defined peptide fragment, it enables researchers to delineate T cell and antibody recognition sites, facilitating the study of antigen processing and presentation. This application is fundamental for understanding immune recognition mechanisms and for the rational design of further immunological studies targeting tumor-associated antigens.

T Cell Response Assays: The peptide is widely adopted in functional assays to evaluate antigen-specific T cell responses. By incorporating NY-ESO-1 (161-180) into in vitro assays such as ELISPOT, intracellular cytokine staining, or tetramer-based flow cytometry, investigators can detect and quantify T cells that recognize this epitope. Such applications are essential for monitoring immune responses in preclinical models, assessing immunogenicity, and validating the efficacy of experimental immunotherapy protocols in a research context.

Antigen Presentation Studies: As a defined peptide epitope, NY-ESO-1 (161-180) is instrumental in studies investigating peptide-MHC binding and antigen processing pathways. Researchers can use it to explore the efficiency and specificity of peptide presentation by various MHC class I or II molecules, providing insights into the molecular determinants of antigen recognition. These studies inform the development of peptide-based immunological reagents and contribute to the broader understanding of antigen processing in tumor immunology.

Peptide-Based Vaccine Research: The sequence is a valuable tool in the development and evaluation of experimental peptide-based vaccine strategies. By incorporating NY-ESO-1 (161-180) into immunization protocols in preclinical research, scientists can assess its ability to elicit robust and specific immune responses. This approach enables systematic investigation of peptide immunogenicity, adjuvant optimization, and the selection of candidate epitopes for further study, supporting the iterative process of vaccine design and refinement.

Quality Control and Analytical Reference: In peptide synthesis and analytical laboratories, NY-ESO-1 (161-180) serves as a reference standard for quality control and method validation. Its well-characterized sequence and physicochemical properties make it suitable for calibrating analytical instruments, validating peptide purification protocols, and benchmarking assay performance. Reliable access to such reference peptides underpins the accuracy and reproducibility of experimental workflows in peptide chemistry and immunological research.

1. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

2. Effect of Short-Term Desiccation, Recovery Time, and CAPA-PVK Neuropeptide on the Immune System of the Burying Beetle Nicrophorus vespilloides

3. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review

4. A possible role of tachykinin-related peptide on an immune system activity of mealworm beetle, Tenebrio molitor L

5. High fat diet and GLP-1 drugs induce pancreatic injury in mice